Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowded field, with Biogen, Novartis, Takeda, Climb Bio and Jade chasing targets such as APRIL, BAFF and CD38. On the latest BioCentury This Week podcast, BioCentury's analysts assess how next-generation therapies are competing on safety and longer dosing intervals. The analysts also discuss Heidi Overton's FDA commissioner confirmation hearing and li...

🔥❤️ في هذا الفيديو، يظهر موزو بإطلالة جديدة ويفاجئ المتابعين بخطوة غير متوقعة. 😳✨ لكن ماذا يحدث لموزو في المستشفى؟ 🏥👀😱❤️ موقف أثار فضول المعجبين وجعل الكثيرين يتساءلون عمّا حدث بالفعل.🥰 تابعوا الفيديو حتى النهاية لاكتشاف جميع التفاصيل ومتابعة آخر المستجدات!👍 لا تنسوا الإعجاب، 💬 التعليق، 📲 المشاركة، والاشتراك في القناة 🔔❤️.

Send us Fan Mail This episode of "The UMB Pulse" explores why health care can feel fragmented when patients must repeat medical histories and providers don’t seem to communicate. Kenneth H. Wong, PhD, University of Maryland, Baltimore’s vice provost for graduate education and dean of the School of Graduate Studies, explains that the issue is driven less by individual unwillingness than by systems and structures that discourage coordination and lack a clear “general contractor” role. He...

Why are we here? Does life, or the universe, mean anything? And if it does, what? Today on ID The Future, host Andrew McDiarmid explores those questions and more with physicist and author Dr. Eric Hedin. Using the recent documentary film The Story of Everything as a springboard for discussion, Hedin shows that cumulative scientific evidence is pointing to a purposeful universe, not a cosmic accident. This is Part 1 of a two-part conversation. Look for Part 2 next!Source

Oncolytic viruses may offer a new way to tackle solid tumors by targeting cancer cells and activating the immune system. Dr. Eric Poma explains how Calidi Biotherapeutics is engineering a vaccinia-based virus to evade immune clearance, reach tumors, and deliver an immune-stimulating payload. He and Kevin Folta discuss the approach’s potential for cancers such as lung cancer, melanoma, renal cancer, and head and neck cancers.

Oncology AI is moving closer to clinical decisions: estimating treatment benefit, mapping risk, and handling incomplete evidence. This coverage shows why stronger prediction and better care remain separate…

Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the case for compounding pharmacies to set their own safety standards.

Christophe has run MedinCell since 2009, when it was eight people in a converted garage. Today it's one of only three French biotechs to ever cross $1B on Euronext.With one Teva-partnered product already a commercial success, the partners are potentially weeks away from getting FDA approval for a second.We also talked about France’s biotech giants, the landscape of long-acting injectables, and why Christophe was once in charge of a remote fishing lodge in Canada.---Discover the best biotech

n this episode of The Cancer Project, we sit down with ovarian cancer survivor and author Anna Focht. In 2015, what began as a routine annual appointment quickly changed Anna’s life when her doctor discovered a lump during a pelvic exam. Diagnosed with stage three B ovarian cancer, Anna underwent surgery followed by 18 weeks of chemotherapy while navigating treatment and trying to remain present for her family.Anna opens up about the physical and emotional realities of her cancer journey, from the

Co-Founder & Partner Sascha Oliver Bucher describes the firm and investments it has been making, and shares his thoughts on the VC ecosystem in Europe.

Gianni Cesareni (Professor Emeritus, University of Rome Tor Vergata and fromer Group Leader, EMBL Heidelberg, 1979-88) chats with Thomas Vaccari (Current Professor, University of Milan and former Predoctoral Fellow, EMBL Heidelberg, 1999-2004). Gianni reflects on his unconventional journey from physics to molecular biology, his formative postdoctoral years alongside Nobel laureates in Cambridge, and how interdisciplinary training shaped his scientific career. He also discusses how EMBL's

🧠 JOIN THE GIANT'S SHOULDER FAMILYBecome a YouTube Member for exclusive episodes, early access + ad-free viewing 👇 https://www.youtube.com/@thegiantsshoulder/joinJohn Vervaeke is an award-winning cognitive scientist at the University of Toronto, where he directs the Cognitive Science programme and the Consciousness and Wisdom Studies Laboratory. He helped pioneer relevance realisation — the claim that underneath your intelligence, your attention and your consciousness sits a single process, and

🎬 EPISODE OVERVIEWThe Longevity Consortium is mapping the biology of aging. We review the NIH-funded research aiming to delay chronic disease.The NIH-supported Longevity Consortium is a massive effort to understand the biology of aging to reduce risks of cancer, dementia, and frailty. We examine their five core focus areas, ranging from exceptional longevity cohorts to candidate drug screening. Dr. Nik Schork and Dr. George Murphy break down the current strategy for targeting age-related

Adding under-canopy lighting changes more than light distribution. It can also change how much pruning and defoliation your crop actually needs.In this episode, we look at how under-canopy lighting can influence canopy management and why traditional pruning strategies may need to be reconsidered when more light is reaching deeper into the plant. Instead of automatically removing lower growth, cultivators can evaluate whether those flower sites are now receiving enough light to remain productive.We

Jimmy Bechtel sits down with Mike Hutton of Almac Clinical Technologies to talk about where site burden really starts, and what sponsors can do earlier in study design to reduce it. They dig into the difference between protocol complexity and operational complexity, why fragmented systems and workflows quietly pile friction onto site staff, and what a more connected, site-first approach to trial design actually looks like. Mike also shares the one question he wishes more sponsors would ask si...

In this episode of The BioHub by Avetix, I’m joined by Dan O’Connell, President and CEO of Acumen Pharmaceuticals.Dan shares his journey from neuroscience investing and company creation into the CEO role, and how he has helped take Acumen from a private, preclinical biotech into a publicly traded clinical-stage company focused on Alzheimer’s disease.We discuss the origins of Acumen, what it was like taking the company public with just nine people, navigating a difficult few years for biotech,

Join Dr Adrian Sie, a leading consultant in paediatrics and allergy specialist, and Tracey Dunn, Education and AllergyWise manager, as they discuss the often misunderstood topic of nut-free schools. They’ll look at the common misconceptions made about nut-free environments and what the evidence tells us when it comes to making children safer in school. Both Adrian and Tracey share their expert perspectives on the pros and cons of nut-free environments. Whether you're a parent, teacher, or simply

In this episode of The Future Conceived, host Dr. Jeremy Egbert sits down with Dr. Kahina Boukherroub to explore the unique world of avian reproductive biology. Dr. Boukherroub breaks down how 3D tissue organoids are transforming poultry research, offering key insights into antioxidant pathways to improve turkey fertility and exploring how the reproductive tract responds to pathogens like avian influenza. Beyond the bench, Dr. Boukherroub offers practical, encouraging advice for early-career...

Leaves turn yellow in the fall because Chlorophyll breaks down, revealing the yellow pigment that was there all along. But why red? Red is a different story altogether. Leaves have to make a new pigment to turn red. Why would a dying leaf go an extra mile to do that? Scientists don’t really know. NPR science correspondent Nell Greenfieldboyce reports on the leading hypotheses out there.Read more of Nell's reporting on this topic. Interested in more seasonal science? Email us your ideas at

Dr. Don and Professor Ben talk about the risks from eating Super Greens recalled for Salmonella contamination. Dr. Don - risky ☣️ Professor Ben - risky ☣️ Actual distribution of Cronobacter spp. in industrial batches of powdered infant formula and consequences for performance of sampling strategies - ScienceDirect Superfoods Inc. dba Live it Up. Recalls Live it Up Super Greens Because of Possible Health Risk | FDA Survival of Salmonella enterica in Military Low-Moisture Food Products during